Corporate Banner
Satellite Banner
ADME Tox
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Ferrer Announces Best-in-Class Results in Phase I for Lorediplon in Insomnia

Published: Wednesday, February 15, 2012
Last Updated: Tuesday, February 14, 2012
Bookmark and Share
Ferrer now seeking development partners for Lorediplon that has demonstrated a highly promising efficacy, safety and tolerability profile.

Ferrer has announced that it has completed phase I clinical trials of Lorediplon in insomnia. The trials demonstrated the orally available compound has a best-in-class efficacy profile in terms of sleep maintenance and sleep quality when compared to market leader zolpidem.

The pharmacodynamic effects of a single oral administration of Lorediplon (at 1mg, 5mg and 10mg doses), zolpidem (10mg) and placebo, were assessed in 34 healthy adult subjects employing a phase advanced model of insomnia, in which subjects retire to bed five hours earlier than normal and are required to stay there until early morning.

In this model Lorediplon demonstrated dose related clinical benefits in measured sleep parameters that were either comparable to or exceeded zolpidem, in terms of the duration and quality of sleep that subjects achieved.

Lorediplon was safe and well tolerated, with no residual effects observed up to 14 hours after dosing.

In addition, Lorediplon has proven safe and well tolerated in the 129 subjects involved in all Phase I clinical studies.

"Insomnia remains a common sleep disorder that has both a significant impact on an individual's quality of life and broader impact on society, in terms of reduced productivity and associated healthcare costs," says Antonio Guglietta, R&D director at Ferrer.

Guglietta continued, "Lorediplon is the first product to enter clinical trials from our CNS discovery program, the aim of which is to deliver differentiated products targeting underserved needs in insomnia and related sleep disorders. Having demonstrated the clinical benefits, safety and tolerability of Lorediplon, we are actively seeking partners to further the worldwide clinical development and commercialization of Lorediplon."

The emerging clinical and preclinical profile of orally available Lorediplon supports further development as a potential best-in-class non-benzodiazapine (BZD) treatment for sleep insomnia, both in terms of efficacy (improved sleep maintenance and quality), tolerability and the absence of next-day residual effects associated with other treatments in this class.

Lorediplon is the subject of a number of granted and pending patents and is available for further development and commercialization worldwide from Ferrer.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Absorption, Tolerability and Safety Study for Novel Antibacterial Compound Completed
Ferrer announced it has successfully completed a clinical trial, in adult and juvenile patients with impetigo, involving Ozenoxacin formulated as a topical treatment.
Friday, October 19, 2012
Scientific News
New Material Opens Possibilities for Super-Long-Acting Pills
A pH-responsive polymer gel could create swallow able devices, including capsules for ultra-long drug delivery.
Long-sought Discovery Fills in Missing Details of Cell 'Switchboard'
A biomedical breakthrough reveals never-before-seen details of the human body’s cellular switchboard that regulates sensory and hormonal responses.
Tracking Breast Cancer Before it Grows
A team of scientists led by University of Saskatchewan researcher Saroj Kumar is using cutting-edge Canadian Light Source techniques to screen and treat breast cancer at its earliest changes.
Zebrafish Reveal Drugs that may Improve Bone Marrow Transplant
Compounds boost stem cell engraftment; could allow more matches for patients with cancer and blood diseases.
Teeth Reveal Lifetime Exposures to Metals, Toxins
Researchers have identified dental biomarkers to reveal links between early iron exposure and late life brain diseases.
An Innovative Algorithm to Decipher How Drugs Work Inside the Body
Researchers at Columbia University Medical Center (CUMC) have developed a computer algorithm that is helping scientists see how drugs produce pharmacological effects inside the body.
Uncovering the Spread of Bacteria in Pneumonia
Northwestern Medicine scientists have discovered the role a toxin produced by a pneumonia-causing bacterium plays in the spread of infection from the lungs to the bloodstream in hospitalized patients.
Ferring Bets on Bacteriophages to Treat Inflammatory Bowel Disease
Ferring Pharmaceuticals have annoucned that it will collaborate with Intralytix in the latest phase of its early stage development programme for a bacteriophage-based therapy for inflammatory bowel disease (IBD).
Rare Form: Novel Structures Built from DNA Emerge
DNA, the molecular foundation of life, has new tricks up its sleeve. The four bases from which it is composed can be artificially manipulated to construct endlessly varied forms in two and three dimensions.
RNAi Screening Trends
Understand current trends and learn which application areas are expected to gain in popularity over the next few years.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!